SDZ Stock Analysis: Sandoz | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 31.846m CHF | 12M Return: 38.5% | CH1243598427 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 58.6M
Rev. Trend: 62.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 2.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sandoz Group AG is a Swiss-headquartered pharmaceutical company that develops, manufactures, and markets generic medicines and biosimilars globally. The companys portfolio spans a broad range of therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, respiratory, immunology, and ophthalmology, and it also supplies active pharmaceutical ingredients (APIs) and finished dosage forms.
Founded in 1886 and based in Basel, Sandoz operates in the specialty and generic drug manufacturing segment of the healthcare sector. The generics and biosimilars business model focuses on producing lower-cost alternatives to off-patent branded pharmaceuticals, with revenue typically driven by volume and cost efficiency rather than premium pricing. Sandoz was spun off from Novartis as an independent publicly listed company in 2023.
- Biosimilar portfolio expansion accelerates segment revenue growth
- US generic pricing pressure compresses operating margins
- European currency headwinds and price caps limit reported growth
| Net Income: 648.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.27 > 1.0 |
| NWC/Revenue: 3.88% < 20% (prev 20.35%; Δ -16.46% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.92b > Net Income 648.3m |
| Net Debt (5.35b) to EBITDA (2.34b): 2.29 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (438.4m) vs 12m ago 1.43% < -2% |
| Gross Margin: 47.54% > 18% (prev 46.60%; Δ 0.93% > 0.5%) |
| Asset Turnover: 51.91% > 50% (prev 43.15%; Δ 8.76% > 0%) |
| Interest Coverage Ratio: 8.15 > 6 (EBIT TTM 1.76b / Interest Expense TTM 215.6m) |
| A: 0.02 (Total Current Assets 8.81b - Total Current Liabilities 8.36b) / Total Assets 22.9b |
| B: 0.37 (Retained Earnings 8.43b / Total Assets 22.9b) |
| C: 0.08 (EBIT TTM 1.76b / Avg Total Assets 22.2b) |
| D: 0.65 (Book Value of Equity 9.02b / Total Liabilities 13.8b) |
| Altman-Z'' = 2.55 = A |
| DSRI: 0.88 (Receivables 2.95b/2.69b, Revenue 11.5b/9.32b) |
| GMI: 0.98 (GM 46.60% / 47.54%) |
| AQI: 0.94 (AQ_t 0.49 / AQ_t-1 0.52) |
| SGI: 1.24 (Revenue 11.5b / 9.32b) |
| TATA: -0.06 (NI 648.3m - CFO 1.92b) / TA 22.9b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of August 29, 2026, the stock is trading at CHF 68.90 with a total of 903,337 shares traded. Over the past week, the price has changed by -6.69%, over one month by +5.93%, over three months by +5.48% and over the past year by +38.48%.
Current recommended Stop Loss: 65.50 (which is 4.9% or 1.7 ATR below the current price).
Sandoz has no consensus analysts rating.
Market Cap USD = 39.6b (31.8b CHF * 1.2433 CHF.USD)
P/E Trailing = 61.8487
P/E Forward = 19.9601
P/S = 2.7275
P/B = 4.3942
P/EG = 1.1718
Revenue TTM = 11.5b USD
EBIT TTM = 1.76b USD
EBITDA TTM = 2.34b USD
Long Term Debt = 4.70b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.45b USD (from shortTermDebt, last quarter)
Debt = 6.60b USD (from shortLongTermDebtTotal, last quarter) + Leases 385.0m
Net Debt = 5.35b USD (calculated: Debt 6.60b - CCE 1.25b)
Enterprise Value = 44.9b USD (39.6b + Debt 6.60b - CCE 1.25b)
Interest Coverage Ratio = 8.15 (Ebit TTM 1.76b / Interest Expense TTM 215.6m)
EV/FCF = 41.55x (Enterprise Value 44.9b / FCF TTM 1.08b)
FCF Yield = 2.41% (FCF TTM 1.08b / Enterprise Value 44.9b)
FCF Margin = 9.37% (FCF TTM 1.08b / Revenue TTM 11.5b)
Net Margin = 5.62% (Net Income TTM 648.3m / Revenue TTM 11.5b)
Gross Margin = 47.54% ((Revenue TTM 11.5b - Cost of Revenue TTM 6.05b) / Revenue TTM)
Gross Margin QoQ = 46.61% (prev 48.43%)
Tobins Q-Ratio = 1.97 (Enterprise Value 44.9b / Total Assets 22.9b)
Interest Expense / Debt = 3.26% (Interest Expense 215.6m / Debt 6.60b)
Taxrate = 23.20% (195.8m / 844.2m)
NOPAT = 1.35b (EBIT 1.76b * (1 - 23.20%))
Current Ratio = 1.05 (Total Current Assets 8.81b / Total Current Liabilities 8.36b)
Debt / Equity = 0.73 (Debt 6.60b / totalStockholderEquity, last quarter 9.02b)
Debt / EBITDA = 2.29 (Net Debt 5.35b / EBITDA 2.34b)
Debt / FCF = 4.95 (Net Debt 5.35b / FCF TTM 1.08b)
Total Stockholder Equity = 8.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.92% (Net Income 648.3m / Total Assets 22.9b)
RoE = 7.33% (Net Income TTM 648.3m / Total Stockholder Equity 8.85b)
RoCE = 12.97% (EBIT 1.76b / Capital Employed (Equity 8.85b + L.T.Debt 4.70b))
RoIC = 8.78% (NOPAT 1.35b / Invested Capital 15.4b)
WACC = 7.27% (E(39.6b)/V(46.2b) * Re(8.06%) + D(6.60b)/V(46.2b) * Rd(3.26%) * (1-Tc(0.23)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.22 | Cagr: 0.82%
[DCF] Terminal Value 77.97% ; FCFF base≈775.5m ; Y1≈888.9m ; Y5≈1.31b
[DCF] Fair Price = 33.13 (EV 19.7b - Net Debt 5.35b = Equity 14.3b / Shares 432.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 62.45 | Revenue CAGR: 14.72% | SUE: 1.61 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.03 | Chg30d=-1.78% | Revisions=-18% | GrowthEPS=+10.6% | GrowthRev=+9.1%
EPS next Year (2027-12-31): EPS=4.56 | Chg30d=-1.24% | Revisions=+10% | GrowthEPS=+13.2% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: -6% (up=7, down=8)